← Leaderboards
Xincheng Zheng
Oncoimmune, Ltd
$2,277,490
Attributed
$2,277,490
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–09$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$2,277,490 · 1
By mechanism
R44$2,277,490 · 1
Top collaborators
No co-investigators on record.
Most similar at Oncoimmune, Ltd
Same institution · by research overlap
- Qunmin Zhou$614,992
- Xingluo Liu$145,246
Others in their field
Top investigators on “Membrane Glycoproteins”
- Dennis R. Burton · Scripps Research Institute$199,946,411
- Joseph G Sodroski · University Of Pennsylvania$40,634,244
- Wesley Ian Sundquist · Utah State Higher Education System--University Of Utah$24,729,408
- Priyamvada Acharya · Duke University$22,310,128
- Anne Moscona · Mount Sinai School Of Medicine Of Nyu$21,159,268
- Bing Chen · Boston Children'S Hospital$19,049,529
Research focus
Membrane GlycoproteinsMultiple SclerosisLeadLigandsCell LineMouse ModelAutoimmune DiseasesClinical TrialsAcuteCollaborationsCyclic GmpDrug Delivery SystemsChimeric ProteinsAdoptedChronicExperimental Autoimmune EncephalomyelitisExtracellular DomainGeneticBaseGrantHalf-LifeIgg1In VivoNatural Regeneration
Grant awards (3)
CD24 as Therapeutic Target for Multiple Sclerosis-phase II Competing Renewal$1,444,734
R44 · FY2009 · NS · contact PI
CD24 as Therapeutic Target for Multiple Sclerosis-phase II Competing Renewal$469,280
R44 · FY2008 · NS · contact PI
CD24 as therapeutic target for multiple sclerosis-phase2$363,476
R44 · FY2005 · NS